Equities

ARCA Biopharma Inc

ARCA Biopharma Inc

Actions
Health CarePharmaceuticals & Biotechnology
  • Price (USD)4.75
  • Today's Change0.300 / 6.74%
  • Shares traded1.46m
  • 1 Year change-16.96%
  • Beta2.7895
Data delayed at least 15 minutes, as of Jan 19 2021 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Events & Activity

  • ABIO:NAQ trading volume exceeds daily average by +15.07%
  • ABIO:NAQ price moved over +1.56% to 4.55

Key statistics

On Tuesday, ARCA Biopharma Inc (ABIO:NAQ) closed at 4.75, 114.93% above the 52 week low of 2.21 set on Mar 19, 2020.
52-week range
Today
2.21Mar 19 202022.00May 28 2020
Markit short selling activity
Low
Med
High
Open4.48
High4.80
Low4.43
Bid4.66
Offer4.69
Previous close4.45
Average volume385.91k
Shares outstanding9.32m
Free float9.28m
P/E (TTM)--
Market cap41.48m USD
EPS (TTM)-2.65
USD
Data delayed at least 15 minutes, as of Jan 19 2021 21:00 GMT.
More ▼
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.